small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search
  • Professionals (357)
  • Capabilities (78)
  • Experience (153)
  • Insights & News (2,358)
  • Other Results (96)

Professionals 357 results

Oscar David
Oscar David
Partner
  • Chicago
Email
+1 312-558-5745
vCard

Partner

  • Chicago
Sandra Edwards
Sandra Edwards
Partner
  • San Francisco
Email
+1 415-591-1412
vCard

Partner

  • San Francisco
Amanda Groves
Amanda Groves
Partner
  • Los Angeles, 
  • San Francisco
Email
+1 213-615-1851
vCard

Partner

  • Los Angeles
  • San Francisco
View All Professionals

Capabilities 78 results

Practice Area

Product Liability & Mass Torts

Major multinational companies trust Winston to defend their products and reputations in high-profile, high-stakes product liability and mass tort claims. Our Product Liability & Mass Torts Practice is one of the industry’s most seasoned, with a deep bench of experienced lawyers and a unique combination of extensive trial experience and expansive technical knowledge....Read more

Practice Area

Derivatives & Structured Products

Winston represents swap dealers, major swap participants, financial intermediaries, hedge funds, national exchanges, and end-users in a broad array of derivative transactions ranging from highly structured transactions to more traditional trading or hedging transactions, and in regulatory and enforcement issues related to commodities and derivatives....Read more

Industry

Consumer Financial Services

The financial services landscape is undergoing rapid and unprecedented transformation—driven by technological innovation, evolving market dynamics, and a shifting regulatory climate. Winston & Strawn is uniquely positioned to help clients not only adapt to these changes, but to anticipate what’s next....Read more

Experience 153 results

Experience

|

March 3, 2026

Representing Farmer Bros in its Sale to Royal Cup

Winston & Strawn LLP is representing Farmer Bros. Co. (Nasdaq: FARM), a leading roaster, wholesaler and distributor of coffee, tea and allied products, in its sale to Royal Cup, Inc., a manufacturer and distributor of premium coffee and tea and portfolio company of Dallas-based private equity firm Braemont Capital, in an all-cash transaction.  ...Read more

Experience

|

January 22, 2026

Advised SQM on US$600M offering of subordinated capital notes due 2056 (Hybrid Bond Offering)

Winston & Strawn LLP advised longstanding client Sociedad Química y Minera de Chile S.A. (“SQM”) (NYSE: SQM) on its US$600 million offering of subordinated capital notes. The notes were offered in the United States pursuant to Rule 144A and outside the United States pursuant to Regulation S.The subordinated capital notes are due in 2056 and constitute SQM’s first international hybrid bond issuance, structured to be consistent with SQM’s recent UF 10 million (approximately US$ 430 million) Series S hybrid-subordinated bond issuance in the Chilean securities market. The notes bear an initial annual interest rate of 5.625% and are subject to reset on April 22, 2031 (the “First Reset Date”), and on every fifth anniversary thereafter, based on a spread over the 5-year U.S. Treasury bond rate, with interest rate step-ups on the fifth and twentieth anniversaries of the First Reset Date. The transaction closed on January 22, 2026.BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Santander US Capital Markets LLC, and Scotia Capital (USA) Inc. acted as initial purchasers of the notes.Link Capital Partners was financial advisor to SQM.SQM is a global company with a leading position in the lithium, iodine, and potassium nitrate markets. It develops and produces a diverse range of products for industries essential to human progress, including health, nutrition, renewable energy, and technology, driven by innovation and technological development.The Winston & Strawn team advising on the transaction included corporate partner Sey-Hyo Lee (New York) and foreign legal advisor Bruno M. Fiorino (New York). Partner Katherine Erbeznik (New York) advised on tax matters....Read more

Experience

|

January 21, 2026

Winston Represents Century Park Capital Partners In Its Exit of MCCi

Winston represented Century Park Capital Partners and its portfolio company MCCi, LLC, in connection with an investment by Incline Equity Partners in MCCi. MCCi is a provider of enterprise content management and workflow automation solutions to public sector clients with a comprehensive suite of products that enable state and local governments to solve manual workflow challenges and drive operational efficiency throughout their organizations. Under Century Park's stewardship, MCCi strengthened its position as a leader in business process automation while maintaining its culture of exceptional customer service....Read more
View All Experience

Insights & News 2,358 results

False Claims Act Playbook

|

March 30, 2026

|

7 Min Read

Chicago U.S. Attorney’s Office Named Lead Prosecutorial Partner on Trade Fraud Task Force, Emphasizing DOJ’s Increased Use of False Claims Act in Customs Fraud Cases

On February 24, 2026, the U.S. Department of Justice (DOJ) and the U.S. Department of Homeland Security (DHS) jointly announced that the U.S. Attorney’s Office in Chicago would be a lead prosecutorial partner on the recently launched interagency Trade Fraud Task Force. Originally launched on August 29, 2025, the Trade Fraud Task Force aims to aggressively pursue importers, purchasers, supply chain actors, and other entities engaged in customs fraud, including duty evasion, misclassification of goods, and smuggling of prohibited items. In this article, we evaluate DOJ’s continued commitment to designate substantial resources to its initiative to combat customs and trade fraud.

Non-Fungible Insights: Blockchain Decrypted

|

March 26, 2026

|

6 Min Read

FCA Handbook Application for Regulated Cryptoasset Activities – Key Takeaways from CP26/4

The close of 2025 highlighted the continuing momentum for the digital asset industry, with regulatory developments accelerating rather than slowing.

Capital Markets & Securities Law Watch

|

March 26, 2026

|

5 Min Read

SEC Clarifies the Application of Federal Securities Laws to Crypto Assets

On March 17, 2026, the Securities and Exchange Commission (SEC) and the Commodity Futures Trading Commission (CFTC) issued a joint interpretation clarifying in large part how the federal securities laws apply to certain crypto assets and related market participants.

View All Insights & News

Other Results 96 results

Law Glossary

What Is Consumer Fraud?

Consumer fraud is commonly defined as deceptive business practices that cause consumers to suffer financial or other losses. The victims believe they are participating in a legal and valid business transaction when they are actually being defrauded. Fraud against consumers is often related to false promises or inaccurate claims made to consumers, as well as practices that directly cheat consumers out of their money....Read more

Law Glossary

What Is Consumer Targeting Law?

The protection of consumers’ privacy online is addressed within the field of consumer targeting law. The Federal Trade Commission’s Behavioral Advertising Principles recommend that websites disclose data collection policies, which are used to create consumer-targeted advertising. The FTC also advises that websites allow consumers to opt out of data collection. The FTC Act can be used to charge companies that do not adhere to their stated consumer privacy policies, do not protect consumer data, or do not provide adequate notifications of privacy policy changes. The law does not require all companies to provide privacy policies, though financial firms must disclose their information-sharing policies to their customers....Read more

Law Glossary

What Are Interchangeable Biological Products?

A biological product is interchangeable if it is biosimilar to the reference product and is expected to produce the same clinical result as the reference product in any given patient. A biosimilar product that is deemed to be interchangeable by the FDA means the biosimilar product can be substituted for the reference product by a pharmacist without consulting the prescriber. The specific requirements for substitution vary by state....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2026. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising